Profund Advisors LLC Buys 61,966 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Profund Advisors LLC increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 77.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 141,985 shares of the biotechnology company’s stock after acquiring an additional 61,966 shares during the period. Profund Advisors LLC owned about 0.07% of BioCryst Pharmaceuticals worth $1,107,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Royal Bank of Canada raised its holdings in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 1,458 shares in the last quarter. Captrust Financial Advisors raised its holdings in BioCryst Pharmaceuticals by 7.4% during the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 1,527 shares in the last quarter. Counterweight Ventures LLC raised its holdings in BioCryst Pharmaceuticals by 2.1% during the fourth quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock worth $744,000 after acquiring an additional 2,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares in the last quarter. Finally, Creative Planning raised its holdings in BioCryst Pharmaceuticals by 2.6% during the third quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock worth $672,000 after acquiring an additional 2,280 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 4.2%

BioCryst Pharmaceuticals stock opened at $8.37 on Friday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.31. The stock’s 50 day moving average is $9.17 and its 200-day moving average is $7.95. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -4.70 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same period in the previous year, the company posted $0.20 EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on BCRX shares. Needham & Company LLC dropped their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Citizens Jmp upped their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Wedbush dropped their target price on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.70.

Insider Activity

In related news, insider Alane P. Barnes sold 150,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the sale, the insider directly owned 400,703 shares in the company, valued at approximately $3,666,432.45. The trade was a 27.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.